Latin America Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Research Report - By Treatment, Medication, Psychotherapy, Education or Training & Country (Mexico, Brazil, Argentina, Chile & Rest of Latin America) - Industry Size, Growth, Trends & Forecasts (2024 to 2029)

Updated On: January, 2024
ID: 268
Pages: 145

Latin America ADHD Therapeutics Market Size (2022 to 2027)

ADHD Therapeutics Market in Latin America is expected to reach USD 1.53 billion by 2027 from USD 0.91 billion in 2022, growing at a CAGR of 10.90% from 2022 to 2027.

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurological/psychiatric disorders among children and adolescents. ADHD is commonly observed in children (<12 years of age) compared to adolescents. ADHD is also described as hyperkinetic disorder/ attention deficit or neuropsychiatric disorder. The exact cause for ADHD is unclear but expected to result from genetic factors and environmental influences. ADHD results in improper functioning of the nervous system that leads to attention deficit and hyperactivity/impulsiveness conditions. Specific symptoms that characterize ADHD include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The symptoms of attention deficit hyperactivity disorder (ADHD) are controlled by different modalities such as medication (stimulants-amphetamines; non-stimulants-atomoxetine), psychotherapy (behavior therapy, cognitive behavioral therapy), and education/training (parent management training, family training).

The growing number of learning disability patients, the rising number of treatment solutions, and government initiatives towards adopting innovative neurological disorders therapeutics are some of the major factors driving the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutics market in Latin America.

However, the low adoption of attention deficit hyperactivity disorder therapeutics and the high cost to maintain longer medications for the treatment of ADHD are some of the factors restraining the growth of the ADHD Therapeutics Market in Latin America.

This research report on the Latin America ADHD Therapeutics Market is segmented and sub-segmented into the following categories:

By Medication:

  • Stimulants
  • Non-Stimulants

By Psychotherapy:

  • Behaviour Therapy
  • Cognitive Behavioural Therapy
  • Interpersonal Psychotherapy
  • Family Therapy

By Education or Training:

  • Parent Management Training
  • Social Skills Training
  • School-Based Interventions

By Country:

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Latin American is estimated to do well in the global market during the forecast period. Brazil, followed by Mexico, is expected to occupy the majority of the share in the Latin American market throughout the forecast period.


Companies playing a vital role in the Latin America ADHD Therapeutics Market are Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.).

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample